Australis Capital Past Earnings Performance

Past criteria checks 0/6

Australis Capital's earnings have been declining at an average annual rate of -53.2%, while the Pharmaceuticals industry saw earnings growing at 27.3% annually. Revenues have been growing at an average rate of 93.2% per year.

Key information

-53.2%

Earnings growth rate

-34.7%

EPS growth rate

Pharmaceuticals Industry Growth23.1%
Revenue growth rate93.2%
Return on equity-112.9%
Net Margin-528.7%
Last Earnings Update31 Mar 2022

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Australis Capital makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

CNSX:AUSA Revenue, expenses and earnings (CAD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 229-50240
31 Dec 217-15190
30 Sep 215-30180
30 Jun 212-31150
31 Mar 211-25130
31 Dec 200-39130
30 Sep 200-26110
30 Jun 200-25130
31 Mar 200-23140
31 Dec 190-11120
30 Sep 190-7110
30 Jun 190-470
31 Mar 190-440
31 Dec 180-620
30 Sep 180-500
30 Jun 180-200
31 Mar 180000

Quality Earnings: AUSA is currently unprofitable.

Growing Profit Margin: AUSA is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: AUSA is unprofitable, and losses have increased over the past 5 years at a rate of 53.2% per year.

Accelerating Growth: Unable to compare AUSA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AUSA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (109.7%).


Return on Equity

High ROE: AUSA has a negative Return on Equity (-112.89%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies